Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-5T4 antibody-drug conjugate ASN004

An antibody-drug conjugate (ADC) composed of an antibody directed against 5T4 and conjugated, via a non-cleavable linker, to a proprietary polymer carrying multiple auristatin analog molecules via a cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of ASN004 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell cytosol, free auristatin analog molecules binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:5T4-ADC ASN004
5T4-targeted antibody-drug conjugate ASN004
5T4-targeted dolaflexin ADC ASN004
anti-5T4 ADC ASN004
Code name:ASN 004
ASN-004
ASN004
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search